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ABSTRACT
Background. Irisin and betatrophin are polypeptide 
hormones implicated in glucose metabolism and insu-
lin resistance (IR). Gestational diabetes mellitus (GDM) 
is accompanied by oxidative stress (OS) and the associ-
ation between circulating irisin and betatrophin levels 
and GDM is controversial. The present study aimed to 
investigate the association of second-trimester irisin, 
betatrophin concentrations and their correlations be-
tween serum OS markers in GDM patients.
Methods. The study included 45 GDM patients and 
45-age matched pregnant women as controls. Serum 
fasting glucose, HOMA-IR, ischemia modified albumin 
(IMA), total oxidative stress (TOS), total antioxidant 
status (TAS), oxidative stress index (OSI), irisin and 
betatrophin were measured. 
Results. Serum irisin levels were decreased and TOS and 
OSI levels were found to be increased in the patient 
group. No significant difference was found with respect 
to serum betatrophin and IMA levels between study 
groups. A correlation analysis revealed no correlation 
between serum irisin and other assessed variables. 
Conclusions. Gestational diabetes mellitus is an OS 
condition in addition to being a metabolic disease. 
Although not correlated with OS, irisin but not be-
tatrophin may be a useful biomarker to predict GDM. 
(Clin Diabet 2020; 9; 5: 328–334)
Key words: irisin, betatrophin, oxidative stress, 
gestational diabetes mellitus
Introduction
Gestational diabetes mellitus (GDM) defined as 
an impaired glucose tolerance of varying severity with 
onset or first recognition during pregnancy that may re-
sult in increased negative maternal and fetal outcomes 
[1]. It affects about nearly 15–20% of all pregnancies. 
Despite the increased rates of GDM detection with 
negative perinatal outcomes, the pathophysiologic 
mechanisms underlying GDM are still not fully under-
stood. Recent studies suggest that oxidative stress (OS) 
and several polypeptide hormones apart from insulin 
could affect glucose metabolism and low-grade inflam-
mation [2–4].
Irisin is a fragment of a cell membrane protein 
that is cleaved from the fibronectin type III domain-
containing 5 (FNDC5) in skeletal muscles. Being a 
novel adipokine and myokine, it involves in exercise, 
total body energy expenditure and thermogenesis 
and contributes to the regulation of glucose and lipid 
metabolism in skeletal muscle and adipose tissue by 
improving insulin sensitivity [5]. Lower levels of irisin 
in DM patients supports the idea that irisin could be a 
protective response of organism to early glucose im-
pairments by taking a crucial role in pancreatic b-cell 
function. Nevertheless, to date, there are only a paucity 
of data exists on irisin and human pregnancy including 
GDM [6, 7]. Since irisin could potentially counteract 
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impaired glucose control seen in GDM by improving 
b-cell function, our rationale was to investigate this 
polypeptide hormone and its potential associations 
with other metabolic markers and OS in GDM. 
Betatrophin (also known as lipasin, Hepatocel-
lular Carcinoma-Associated Gene TD26 or ANGPTL8) 
is a stress-response protein and has been introduced 
as a novel adipokine/hepatokine that down-regulates 
expression of adipocyte triglyceride lipase, improves 
glucose tolerance and promotes pancreatic b-cell 
proliferation [8]. Unfortunately accumulating data on 
betatrophin regulation in humans is partly limited to 
patients with adult obesity, fatty liver, diabetes mellitus 
(DM) and peripheral artery disease [9–12]. However, 
regulation of betatrophin as well as its association 
with irisin and other markers of OS have not been 
elucidated yet. 
Oxidative stress is a major culprit in the patho-
genesis of GDM. Enhanced oxidation products such as 
protein carbonyl, glutathione peroxidase and paraoxo-
nase in GDM patients and reduced antioxidant capacity 
suggest that OS is a key factor in the development and 
progression of GDM [13]. It is believed that insulin 
resistance (IR) and glucose tolerance are strictly linked 
with OS levels and this leads to subclinical inflamma-
tion and altered biochemical pathways resulting in 
GDM-associated negative outcomes among pregnant 
women [14]. OS is a feature of normal pregnancy and 
partially produced in the placenta, and is heightened 
in pathological pregnancies including GDM. Although 
elevated levels of OS markers such as advanced glycated 
end products (AGEs), nitrotyrosine, malondialdehyde 
(MDA), and oxidized low-density lipoproteins (Ox-LDL) 
have been shown to be promising biomarkers for GDM, 
there are still debates on other markers including is-
chemia modified albumin (IMA) and total oxidant status 
(TOS) [2, 3, 15, 16]. 
Since GDM is regarded as an OS-related disorder 
and prediabetic condition with an enormous IR and 
inadequate insulin compensation, we hypothesized 
that betatrophin levels may be increased in women 
with GDM and these levels may be correlated with OS 
markers and circulating irisin levels. 
Methods
Study design
This cross-sectional study was conducted in the 
Obstetrics and Gynecology department of Canakkale 
Onsekiz Mart University (COMU) Training and Research 
Hospital. Ethical board approval was obtained from 
COMU Faculty of Medicine Ethical Committee. Informed 
consent was provided by all study participants.
Subjects
From the population of 352 pregnant women rou-
tinely tested for GDM with a 75 g 2-hour oral glucose 
tolerance test (OGTT) between 24th and 28th weeks 
of gestation, 45 patients with GDM and 45 women 
with normal glucose tolerance (NGT), matched for 
age, gestational age and body mass index (BMI) were 
recruited for this study. GDM was diagnosed accord-
ing to the criteria of The International Association of 
Diabetes and Pregnancy Study Groups on the basis 
of one or more of the following threshold glucose 
levels: fasting ≥ 92 mg/dL, 1 h ≥ 180 mg/dL and 2 h 
≥ 153 mg/dL [17]. Pregnant women with conditions 
including obesity, multiple pregnancies, pre-existing 
glucose intolerance, vascular disease, having acute or 
chronic liver or renal disease, polycystic ovary disease, 
preeclampsia and acute or chronic inflammation were 
excluded from the current study. Maternal pregnancy 
characteristics including maternal age, BMI, smoking 
status, gestational weeks at sampling, history of spon-
taneous abortion, first-degree relative with diabetes 
and history of accompanying chronic disease were 
collected and recorded for each subject. 
Biochemical analyses
After an overnight fasting, venous blood samples 
were obtained from each subject to assess study pa-
rameters on the day of OGTT screening. All samples 
were centrifuged within 30 min at 3000 rpm for 15 min 
to separate serum. Serum specimens were aliquoted 
and stored for analysis at –80°C until the biochemical 
estimation of irisin, betatrophin, TOS, TAS, and IMA. 
Insulin resistance was estimated by homeostasis model 
of assessment insulin resistance (HOMA-IR) as sug-
gested by Matthews et al. [18] using serum glucose and 
insulin levels (HOMA-IR = fasting plasma insulin [mU/ 
/mL] × fasting plasma glucose [mg/dL]/405).
Measurement of TOS, TAS and IMA
Serum TAS and TOS levels were measured with 
spectrophotometric kits (Rel Assay Diagnostics, Ga-
ziantep, Turkey) according to the method previously 
described by Jansen and Ruskovska [19]. The results for 
TAS and TOS are expressed as mmol Trolox equivalent/L 
and μmol H2O2 equivalent/L, respectively. IMA meas-
urements were performed according to the colorimetric 
method described by Bar-Or et al. [20]. Results were 
reported in absorbance (ABSU) units.
Determination of the OSI and IMAR
The ratio percentage of TOS to TAS was used 
to calculate the OSI. Specifically, OSI (arbitrary unit) 
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¼ [(TOS, μmol H2O2 equivalent/L)/(TAS, mmol Trolox 
equivalent/L)]. 
After measuring serum albumin concentration with 
a standard commercial kit, IMAR levels were calculated 
as a ratio of IMA to albumin, and the results were ex-
pressed as ABSU/g (absolute unit/gram). 
Irisin and betatrophin measurement
Serum irisin levels were measured using a com-
mercially available enzyme-linked immunosorbent 
assay (ELISA) kit (Eastbiopharm, Hangzhou, China) 
and serum betatrophin concentration was determined 
using a commercially available human ELISA kit (USCN 
Life Science Inc., China) with both an intra- and an 
inter-assay coefficient of variation < 10%. Irisin and 
betatrophin results were expressed as μg/mL and 
ng/mL respectively. 
Statistical analysis
Statistical analysis was performed using SPSS 
19.0 (SPSS for Windows, SPSS, Chicago). Normally 
distributed data were expressed as mean ± standard 
deviation (SD) and non-normally distributed data 
were expressed as median and interquartile range. 
Depending on the distribution characteristics of the 
data parametric or non-parametric statistical tests were 
used. The differences among groups were analyzed 
using the Mann-Whitney U test. Bivariate correlations 
were assessed using standardized Pearson coeffi-
cients. Odds ratios (95% confidence intervals) of the 
independent clinical parameters were calculated with 
univariate and multiple logistic regression models to 
predict GDM. A multivariate logistic regression analysis 
was built by performing stepwise variable selection on 
those variables with a univariate P value < 0.25. The 
P values obtained of less than 0.05 was considered as 
statistically significant.
Results
The mean ages of the women in the GDM and 
control groups were 30.75 ± 4.99 and 28.17 ± 5.15 
years respectively (P = 0.181). Clinical, metabolic and 
laboratory characteristics of patients in both groups 
are represented in Table 1. Blood glucose and OGTT 
measurements were found to be elevated in GDM 
women. HOMA-IR of GDM patients and controls were 
3.36 ± 2.19 and 2.07 ± 1.38 respectively (P = 0.001). 
A statistically significant increase in terms of IMA and 
IMAR was observed in GDM patients (P = 0.001 and P = 
0.002 respectively). Serum irisin levels were 2,62 ± 1,20 
in GDM patients and 3.41 ± 2.22 in healthy pregnant 
women. This difference was found to be statistically 
significant between two groups (P = 0.038) (Fig. 1). 
Betatrophin levels were not found to be significant 
between study groups (P = 0.881).
Correlation analysis revealed a significant correla-
tion between circulating irisin and IMAR (P = 0.012). 
No other significant correlations were found with other 
Table 1. Demographic and laboratory characteristics of gestational diabetes mellitus (GDM) patients and controls
GDM patients (n = 45) Controls (n = 45) P
Maternal age (years) 30.75 ± 4.99 28.17 ± 5.15 0.181
Gravidity [median (min-max)] 2 (1–5) 2 (1–5) 0.122
BMI at the time of OGTT [kg/m2] 25.9 ± 3.9 24.0 ± 4.6 0.056
Fasting blood glucose [mg/dL] 94.48 ± 21.63 79.51 ± 6.76 0.001
OGTT-1st hour [mg/dL] 174.65 ± 32.47 128.35 ± 26.52 0.001
OGTT-2nd hour [mg/dL] 141.78 ± 30.53 106.17 ± 21.77 0.001
Insulin [μIU/mL] 14.35 ± 8.74 10.49 ± 7.00 0.023
HOMA-IR (%) 3.36 ± 2.19 2.07 ± 1.38 0.001
TSH [μIU/mL] 2.40 ± 1.65 2.44 ± 1.17 0.896
Total cholesterol [mg/dL] 217.9 ± 50.6 233.4 ± 37.5 0.102
Triglyceride [mg/dL] 223.0 ± 85.5 202.1 ± 64.6 0.195
Albumin [g/dL] 3.74 ± 0.23 3.90 ± 0.19 0.001
TOS [μmol H2O2 equivalent/L] 11.72 ± 2.48 7.19 ± 3.27 0.001
TAS [mmol Trolox equivalent/L] 0.71 ± 0.30 0.66 ± 0.32 0.501
OSI 21.83 ± 15.65 11.88 ± 9.32 0.002
IMA [ABSU] 0.44 ± 0.08 0.0047 ± 0.05 0.069
IMAR [ABSU/g] 0.12 ± 0.02 0.12 ± 0.01 0.595
Betatrophin [ng/mL] 218.1 ± 244.2 225.2 ± 200.7 0.881
Irisin [μg/mL] 2.62 ± 1.20 3.41 ± 2.22 0.038
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study parameters in GDM patients (Table 2). A multivari-
able analysis revealed that TOS and OSI are significant 
predictors of GDM development (Table 3).
Discussion
Although the present study demonstrated that 
serum irisin levels were significantly lower in GDM 
patients, serum betatrophin levels were found to be 
similar in both study groups. Moreover, serum TOS 
levels and OSI were found to be increased in patients 
with GDM. Interestingly, no significant difference was 
observed between groups in respect to serum IMA 
levels and IMAR measurements. 
Irisin is a recently discovered myokine that is en-
coded by the fibronectin type III domain-containing 
protein 5 (FNDC5) precursor gene. It has been sugges-
Figure 1. Box plot presentation of serum. A — irisin; B — TOS; C — betatrophin; D — OSI levels in study groups
P = 0.038 P = 0.001














Table 2. Correlations between serum TOS, OSI, irisin, and betatrophin with other demographic and laboratory parameters
GDM patients (n = 45)
Betatrophin Irisin TOS OSI
r P r P r P r P
Maternal age (years) –0.86 0.572 0.118 0.442 0.170 0.345 0.121 0.501
BMI at the time of OGTT –0.195 0.200 0.079 0.604 0.156 0.386 0.094 0.601
HOMA-IR 0.022 0.886 0.147 0.335 0.092 0.299 0.162 0.368
TAS 0.013 0.945 –0.144 0.423 –0.117 0.517 –0.882 0.000
IMA –0.144 0.346 0.209 0.168 –0.92 0.610 –0.087 0.629
IMAR –0.101 0.510 0.371 0.012 0.120 0.507 0.094 0.603
OSI –0.175 0.330 0.207 0.248 0.501 0.003
TOS –0.149 0.406 0.368 0.035
Irisin 0.349 0.019
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ted to be involved in mediating the favorable effects 
of exercise on the metabolism and its elevated levels 
induce browning of subcutaneous adipocytes and 
thermogenesis [21]. Moreover, accumulating evidence 
suggests that a decrease in circulating irisin levels may 
be linked with the development of impaired glucose 
metabolism and IR. Due to the vital impacts of irisin on 
body metabolism, several studies have been conducted 
to investigate the association between circulating irisin 
and metabolic disorders. In most of these studies, the 
variation of irisin levels was found to be affected by 
insulin metabolism. However, an association between 
irisin and IR, in particular during pregnancy, seems still 
controversial. In a study by Kuzmicki et al. [7] 130 wom-
en with GDM and 140 BMI-matched pregnant women 
with normal glucose tolerance were investigated. Mean 
irisin levels were found to be lower in patients with 
GDM compared to healthy pregnant women. Similarly, 
Yuksel et al. [6] reported that maternal serum irisin 
levels of patients with GDM were significantly lower 
compared with non-GDM controls. Contrary to these 
findings Ebert et al. [22] and Sancak et al. [23] de-
monstrated no significant difference in GDM patients. 
Therefore, the finding of lower levels of circulating 
irisin in the present study is noteworthy. Unfortunately, 
we didn’t detect any correlation in GDM patients with 
respect to irisin and IR (measured as HOMA-IR). These 
discrepancies may be due to differences in the clinical 
characteristics of the subjects studied. 
Betatrophin is a newly identified liver and adipose 
tissue-derived hormone with implications in the regu-
lation of lipid metabolism, beta-cell replication and 
glucose homeostasis [24]. The scientific evidence linking 
betatrophin with obesity, peripheral artery disease and 
DM is enlarging, but data exploring the association be-
tween betatrophin status and GDM are still controver-
sial [10, 25, 26]. In this regard, some studies reported 
higher betatrophin concentrations in GDM patients, 
while some studies showed the contrary [24, 27–30]. 
Wawrusiewicz-Kurylonek et al. [28] showed that cir-
culating betatrophin levels are dramatically increased 
in pregnancy and are significantly elevated in GDM 
patients compared with healthy pregnants. Similarly, 
Pan et al. [31] found that betatrophin concentration 
was remarkably higher in patients with than without 
GDM. However, Huang et al. [27] demonstrated no 
significant difference between GDM and healthy preg-
nants with respect to circulating betatrophin levels. We 
also observed no significant difference between groups 
in terms of serum betatrophin levels. 
Five oxidative stress parameters were analyzed in 
this study. But only TOS and OSI levels were found to 
be increased in GDM patients. Increased TOS levels and 
reduction in total TAS levels have been implicated in sev-
eral disease states, such as DM, cancer and heart diseases 
[32–34]. But there are only a few studies in literature 
investigated the levels of TOS and TAS in GDM patients. 
Zhou et al. [35] demonstrated that total TOS and TAS 
levels were increased in GDM suggesting that increased 
OS and abnormalities in lipoproteins may be associated 
with the metabolic alterations in GDM. Usluoğulları et 
al. [36] not only reported elevated TOS and OSI levels 
but also decreased irisin levels in GDM patients. As being 
the first study to investigate the relation between serum 
Table 3. Univariate and multivariate logistic regression analysis of study variables  for the prediction of gestational 
diabetes mellitus
Univariable analysis Multivariable analysis
OR 95% CI P value OR 95% CI P value 
Age (years) 1.254 0.824–1.688 0.224
Fasting glucose [mg/dL] 1.091 1.044–1.140 < 0.001 1.068 1.010–1.129 0.022
OGTT-1st hour [mg/dL] 1.053 1.031–1.075 < 0.001 1.039 1.013–1.065 0.002
OGTT-2nd hour [mg/dL] 1.058 1.032–1.084 < 0.001 1.043 1.013–1.075 0.005
Insulin [μIU/mL] 1.068 1.006–1.134 0.031
HOMA-IR (%) 1.534 1.153–2.040 0.003
Albumin [g/dL] 0.037 0.004–0.305 0.002
TOS 1.827 1.277–2.614 0.001 1.762 1.236–2.512 0.002
TAS 0.798 0.168–3.780 0.776
OSI 1.079 1.020–1.142 0.008
IMA [ABSU] 0.742 0.134–2.944 0.083
IMAR [ABSU/g] 0.841 0.234–3.981 0.591
Betatrophin [ng/mL] 1.000 0.998–1.002 0.991
Irisin [μg/mL] 0.992 0.892–1.102 0.878
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irisin levels and TOS, TAS, and OSI in patients with GDM, 
the authors demonstrated a strong correlation between 
TOS and irisin levels suggesting irisin as an OS marker 
and a metabolic protective hormone.
IMA is an “N-terminal modified” albumin which is 
generated immediately following ischemic conditions 
and IMAR is the percentage ratio of IMA to albumin 
that is used to eliminate the effect of reduced albumin 
concentrations. Studies showed that in certain condi-
tions like cirrhosis and preeclampsia IMAR represents 
OS status more effectively [37, 38]. IMA was originally 
evaluated in patients with myocardial ischemia and 
later it has been identified to be helpful for evaluating 
patients with distinct disease conditions including type 
2 DM, coronary ischemia, coronary bypass surgery, 
advanced cancer, systemic sclerosis, pulmonary embo-
lism, liver cirrhosis, and metabolic syndrome [39–41]. 
Although, elevated IMA levels due to the physiologic 
OS state of pregnancy have been demonstrated previ-
ously, Ma et al. [2] was the first that evaluated IMA 
levels in GDM patients. The authors showed that IMA 
levels were elevated in GDM patients with a positive 
correlation with serum glucose levels. Furthermore, 
glycemic levels in GDM were correlated with concentra-
tions of lipid peroxides and increased protein oxidation. 
In the present study, we did not find any significant 
difference between study groups in terms of IMA and 
IMAR. More importantly, there were no correlations 
between IMA and other maternal characteristics. This 
result can be interpreted as IMA was not influenced 
from other metabolic characteristics including IR and 
glucose metabolism. 
A limitation of our study is the limited number of 
study participants. However, we must note that despi-
te the relatively small sample sizes, the validity of our 
results is strengthened by the close matching of study 
groups including age, gestational weeks, gravidity and 
BMI, thus negating these parameters as confounders. 
Another limitation is the variety of physiological factors 
that can affect the levels of IMA in the body. 
In conclusion, the present study confirmed lower 
levels of irisin and increased TOS and OSI as a marker 
of ongoing OS in GDM patients. However, the clinical 
significance of unaltered betatrophin levels demons-
trated in this study remained unclear. Therefore, we 
believe that future large-scale prospective follow-up 
studies are essential for the standardization of irisin, 
betatrophin and OS measurements and also to clarify 
contradictory results.
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